At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 329 enrolled
Drug / intervention
PRO-Kinetic Energy Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent
In Brief
A Phase 3 clinical trial evaluating PRO-Kinetic Energy Stent for Coronary Arteries Disease. Completed, enrolled 329 participants across 35 sites in 5 countries.
Detailed Summary
The purpose of this study is to demonstrate the safety and efficacy of the investigational BIOTRONIK PRO-Kinetic Energy stent in subjects with atherosclerotic disease of native coronary arteries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Arteries Disease
CountriesColombia, Germany, Latvia, Netherlands, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 2012
Enrollment StartNov 2012
Primary CompletionSep 2015
Study CompletionNov 2017
TodayJul 2026
First PostedJun 6, 2012
Enrollment StartNov 1, 2012
Primary CompletionSep 1, 2015
Study CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.1 years ago
Interventions
PRO-Kinetic Energy Stentdevice
Coronary artery stent implant